Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

Asperger's Syndrome: early-phase trial registry

1 of 5 indexed Asperger's Syndrome trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #3,391 of 28,707 conditions by registered trial count.

5 US clinical trials · 1 currently recruiting · #3,391 of 28,707 conditions by registered trial count

Asperger's Syndrome: 5 US clinical trials tracked, 1 recruiting.

Asperger's Syndrome is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is University of South Florida, running 2 of these trials.

Enrollment posture brief

Registry condition aspergers-syndrome

OPEN 1 | RECR 20% | LATE 0 | EARLY 1 | RANK #3391 | SPON 2

Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive (20% recruiting · 10 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Asperger's Syndrome (this)20%
Open-enrollment share among volume-matched conditions near Asperger's Syndrome

Asperger's Syndrome lists 1 open slots (20% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Asperger's Syndrome on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Asperger's Syndrome is recruiting below its size-band peers.

    1 of 5 indexed trials (20%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Asperger's Syndrome research.

    University of South Florida accounts for 2 of 5 trials (40%). 4 distinct sponsors appear on at least one study for this condition label.

  3. Typical Asperger's Syndrome enrolment sits around 214 participants.

    Median target enrolment is 214 among the 5 trials that report a genuine target (sentinel values excluded). 2 of those (40%) plan for fewer than 100 participants.

  4. Asperger's Syndrome research leans observational.

    2 interventional and 3 observational studies make up this index (40% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 21

Phase Distribution

PhaseTrial count
Phase 2 1

Named interventions

Most-linked intervention names on Asperger's Syndrome records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Treatment as Usual Behavioral
2 trials
Standard Practice Cognitive-behavioral therapy Behavioral
1 trials
Personalized Cognitive-behavioral therapy Behavioral
1 trials
Cognitive-behavioral therapy Behavioral
1 trials
SQUED™ series 28.1 home-use Device
1 trials

US sites by state

Facility locations filed on Asperger's Syndrome trials. A trial with sites in several states counts in each.

Florida 2 trials
Maryland 1 trials
Massachusetts 1 trials
Kentucky 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Asperger's Syndrome page

5 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Asperger's Syndrome condition card totals 5 registered trials; most-linked intervention Treatment as Usual; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.